Recently, Fosun Pharma's research report stated that on April 27, Fosun Pharma's board of directors reviewed and approved the proposal to acquire the equity of AlmaLasersLtd. It plans to jointly invest no more than US$240 million with Fosun-Prudential China Opportunities Fund (equivalent to approximately RMB 15). 100 million yuan), the acquisition of Israel AlmaLasersLtd. ("Alma") equity, the proportion of transferred shares is not less than 80% does not exceed 95.6%. Upon completion of the transaction, Fosun Pharma will have a controlling interest in Alma 53.0%-63.3%, with an economic interest of 44.3%-52.9%. The original medical diagnosis and medical device segment of Fosun Pharma has a revenue of 1.06 billion yuan in 2012, of which medical diagnostics and medical device manufacturing business income is 590 million yuan, and medical device agency business income is 470 million yuan. After the analysts judged that the Alma project was completed, the company's medical device business will be transformed from agent to R&D and manufacturing. Alma will become the platform company for the company's high-end medical device international R&D and manufacturing. Alma has an advantage in the high-end medical beauty laser device market: Alma was founded in 1999 and is a world-renowned medical laser, photonic, RF and ultrasonic device manufacturer. The company develops and manufactures Caesarea, based in Israel, and has a North American market support center in Chicago, USA. According to the HarrisWilliams report, Alma has the largest market share (15%) in the world of high-end cosmetic laser devices. Alma entered China in 2003 and has become a leader in China's high-end medical cosmetic laser device market. Alma's layout in the laser medical beauty equipment industry segment: The laser medical beauty equipment industry has three major market segments, namely high-end beauty equipment, medical surgical equipment and household equipment market. Alma is currently one of the market leaders in the high-end beauty market and entered the medical surgery market at the end of 2012. At the same time, Alma has initially completed the research and development reserve for household equipment and is expected to enter by the end of 2013. Alma has leading R&D and technical strength: Dr. Ziv Karni, CEO and founder of Alma, has been engaged in the research and development of medical lasers for more than 20 years and is one of the pioneers in the field of laser medical beauty. By the end of 2012, nearly 40 research and development teams led by him had 74 patents, and another 23 patents had been submitted. M&A price 2012 is about 10.8 times PE. Attractive: As of December 31, 2012, Alma's total assets were US$82.78 million, and shareholders' equity (including preferred shareholders' equity) was US$62.03 million. Total liabilities were 2. US$ 9.74 million; in 2012, Alma achieved operating income of US$ 95.75 million and net profit of US$ 23.3 million. According to the calculation of not less than 80% of the transferable equity of not more than 240 million US dollars and not more than 95.6%, the M&A price is about 10.8 times of PE in 2012, compared with the average of 33 times of PE of A-share medical devices in 2012 and considering Alma's Growth, Alma's valuation is attractive. Soba Noodle,Tartary Buckwheat,Sesame Soba Noodles,Soba Cup Noodles Huantai Biotechnology Co., Ltd. , https://www.huantaifds.com